BioLineRx Ltd. (BLRX)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About BioLineRx Ltd.
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 304K | 427K | 194K | 477K |
| Gross Profit | 232K | 343K | 154K | 382K |
| Operating Income | -2.3M | -2.2M | -3.4M | -3.0M |
| Net Income | -3.9M | -977K | -1.4M | -1.6M |
| Diluted EPS | $0.00 | $0.00 | $nan | $0.00 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 4.8M | 28.9M | 1.2M |
| Gross Profit | 0.00 | 1.1M | 19.7M | 950K |
| Operating Income | -29.2M | -43.0M | -19.2M | -10.3M |
| Net Income | -25.0M | -60.6M | -9.2M | -1.2M |
| Diluted EPS | $-18.00 | $-36.00 | $-6.00 | $0.00 |